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Abstract
The medical profession has been generally very slow to acknowledge the importance of
sleep medicine and sleep research. Disorders of sleep are related to anxiety, many mental
and neurodegenerative diseases, cardiovascular and respiratory disorders, and obesity.
Our knowledge of the neural substrates of sleep/wake states and sleep-related behavior
disorders regulation in health and the diseases, over more than 50 years of sleep research,
is based on the experiments in animal models, pharmacotherapy, and the neuropatho‐
logical studies in humans. But, we still need further work in fundamental multidiscipli‐
nary and clinical research between sleep and neurodegenerative disease investigators to
understand normal and abnormal sleep, and to provide new insights into preventive or
disease-altering approaches for therapy.
Our aim is to give an overview of our recent results related to the importance of thalamo-
cortical cholinergic brain system in the disorders of sleep and motor control during
sleep, with particular relevance to Parkinson’s disease.
Keywords: sleep, motor control, the pedunculopontine tegmental nucleus (PPT), exci‐
totoxic lesion, rat
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1. Introduction
1.1. Importance of sleep research
The medical profession has been generally very slow to acknowledge the importance of sleep
medicine and sleep research. The tendency to sleep less — perhaps 20% less in industrial‐
ized countries than a century ago — has serious consequences for economy and public safety.
According to US National Science Foundation data, 75% of patients report sleep problems, but
less than one-third were asked by their doctors about it, and one-third of American drivers
admit to having nodded off behind the wheel [1]. Furthermore, the mounting body of evidence
links lack of sleep to anxiety, many mental and neurodegenerative diseases [2–4], cardiovas‐
cular and respiratory disorders [5, 6], and obesity [7–9].
On the other hand, our knowledge of the neural substrates for sleep/wake states and sleep-
related behavior disorders regulation in health and the diseases, over more than 50 years of
sleep research, is based on the experiments in animal models, pharmacotherapy, central
nervous system lesions, and the neuropathological studies in humans [2].
But, we still do not know why we sleep [10], and only further work in fundamental multidis‐
ciplinary and clinical research between sleep and neurodegenerative disease investigators is
promising to enable us understand normal and abnormal sleep, and to provide new insights
into preventive or disease-altering approaches for therapy.
1.2. Sleep and neurodegenerative diseases
Sleep is a complex, global and reversible behavioral state of all mammals, that is homeostati‐
cally regulated [11, 12]. It is also defined as a rapidly reversible state of immobility and reduced
sensory responsiveness [12]. Still, there is no definition that has succeded in satisfying all
aspects of sleep. The failure to define sleep as a single behavior lies in several facts [11, 13]: (1)
sleep is not a homogenous state, but continuum of a number of mixed states; (2) the control
mechanisms of sleep are manifested at all levels of biological organization - from genes and
intracellular mechanisms to the networks of neuronal populations within the central nerv‐
ous system that control movement, arousal, autonomic functions, behavior and cognition; (3)
the activity and interactions of these neurochemically greatly heterogenous neuronal popula‐
tions are dependent on two nested biological rhythms — the circadian rhythm of wake/sleep
and about 90 minutes long periodic cycles of non-rapid-eye-movement (NREM)/ rapid-eye-
movement (REM) sleep as two main sleep states [11–13].
Brain neurodegenerative diseases, like Alzheimer’s (AD), and Parkinson’s (PD) diseases, are
devastating and rather common diseases. According to Nussbaum and Ellis [14] their
prevalence is 0.5–1%; increasing to 1–3% for PD, and up to 50% for AD in ages over 69. In spite
of a long knowledge of their clinical description and brain pathology (lesions of the choliner‐
gic neurons in basal forebrain, lesions of the dopaminergic neurons in substantia nigra, etc.),
they remain incurable with only limited success in temporal amelioration of their symptoms.
Their symptoms are either cognitive (dementia in AD), or motor (tremor and bradykinesia in
PD) or eventually both, and with age they progress to affective and cognitive deterioration as
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well as autonomic and sleep related behavioral disturbances. Clinical symptoms first appear
at 65–69 years on average, but there are indications that subclinical features may start many
years earlier. Namely, the patients with REM sleep behavior disorder (RBD) face close to a 20%
5-year risk of developing PD or dementia, and that risk rises to more than 40% after 10 years,
and exceeds 50% after 12 years.
It is well known that human development, maturation, healthy aging [15, 16], and many
neurological diseases [2] are associated with profound changes in sleep/wake states distribu‐
tion and with variety of the sleep-related behavioral disorders. Neurodegenerative diseases
such as AD and PD involve the selective loss of specific neuronal populations within the brain.
Human studies evidenced that sleep/wake cycle disturbance, as no cognitive symptom of
dementia, precedes on average 3 years before the clinical diagnosis of the AD [17], and that
RBD, reflecting an underlying synucleinopathy neurodegeneration, precedes as a symptom
the onset of motor and cognitive disturbances by years or decades, with presence of the α –
synuclein protein pathology within the REM sleep-related regulatory structures of the dorsal
midbrain and pons at the onset of disease, with ascending pattern of neurodegeneration
progression from brainstem to basal areas of the brain [3].
1.3. Sleep and the brain cholinergic systems
Generally, the activation state of mammalian neocortex is regulated by a complex interplay of
cortical and subcortical neuronal networks. Slow EEG oscillations are present in isolated
neocortical tissue, while high-frequency oscillations (β and γ frequency oscillations) are not,
suggesting a dependence on subcortical impulse flow [18]. The cholinergic afferent fibers
system originating in the basal forebrain plays a critical role in switching cortical activity from
deactivated slow to high-frequency, activated EEG patterns. Inputs to the cortex originated in
the thalamus constitute the second major system involved in regulation of the cortical activity,
and the pedunculopontine tegmental nucleus (PPT - the cholinergic nucleus within the pons;
the main thalamo-cortical cholinergic source of innervation) efferent fibers exert, through the
thalamus, widespread control over neocortical EEG activation during waking and REM sleep.
Because direct projections from the PPT reach both the basal forebrain and thalamus, this
nucleus is an ideal candidate to study the integrated contributions of these two systems to
regulating activation of the neocortex [18]. PPT is postulated to have important functions
relevant to the regulation of REM sleep [19, 20], arousal [21–29], and various motor control
systems [30–32], including breathing control [33–38]. In addition, the PPT has a central role in
the REM sleep phenomenon control [39–41], and each individual REM-sleep-sign generating
nucleus receives afferent inputs from PPT [28].
Degeneration of the PPT thalamo-cortical cholinergic neurons was related to RBD [42], and to
the motor control impairment, including falls in PD [43, 44.] Recent PET imaging [45] and
neuropathological studies [44] suggested that the neurodegeneration of thalamic cholinergic
afferent projections may contribute to the PD specific motor and cognitive abnormalities [45].
Clinical studies also evidenced the beneficial effect of AChE inhibitor donepezil in 50%
reduction of falls in PD patients [46], and suggested that PD is a neurodegeneration of different
CNS systems [44].
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Obviously, counseling and prevention of AD or PD would be highly enriched by the devel‐
opment of a practical, sensitive and reliable methodology for detecting those patients with
RBD, or other sleep disorders who are at risk for developing AD or PD.
In this chapter we will give an overview of our results in the animal studies related to the
importance of thalamo-cortical cholinergic brain system (the PPT cholinergic neurons) in the
disorders of sleep and motor control during sleep, which is of particular relevance to PD.
2. Experimental procedure in the animal studies of the impaired PPT
cholinergic control
2.1. The rat model of impaired PPT cholinergic innervation
In our studies we used the bilateral PPT lesioned rats as the “in vivo” model of the severe
thalamo-cortical cholinergic neuropathology. We followed the sleep/wake states architec‐
ture and transition structure, the EEG microstructure and motor control across sleep, and all
the sleep state episodes dynamics. Adult, male, Wistar rats were chronically implanted for
sleep recording [47, 48]. During operative procedure for the stereotaxic implantation of the
EEG and EMG electrodes the bilateral PPT lesions were performed by the stereotaxically
guided microinfusion of 100 nl of 0.1 M ibotenic acid/ 0.1 M phosphate buffered saline into the
PPT of each brain side [49–53].
The animals were maintained on a 12-hour light-dark cycle, and were housed at 25°C with free
access to food and water, and all experimental procedures were in accordance with the EEC
Directive (86/609/EEC) on the protection of animals used for experimental and other scientif‐
ic purposes, and were approved by the Ethical Committee for the Use of Laboratory Animals
of the Institute for Biological Research "Sinisa Stankovic", University of Belgrade (Approval
No 2-21/10).
2.2. Surgical procedure of the chronic electrodes implantation for sleep recording in rat
We implanted under ketamine/diazepam anesthesia (Zoletil 50, VIRBAC, France, 50 mg/kg;
i.p.), in 2.5 months old rats, 4 epidural parietal stainless-steel screw electrodes for electroen‐
cephalographic (EEG) cortical activity recording: 2 in the motor (MCx; A/P: +1.0 mm from
bregma; R/L: 2.0 mm from sagittal suture), and 2 in the sensorimotor (SMCx; A/P: -3.0 mm
from bregma; R/L: 2.0 mm from sagittal suture) cortex [54]. Bilateral electromyogram (EMG)
stainless steel teflon coated wire electrodes (Medwire, NY, USA) were implanted into the
dorsal nuchal musculature to assess skeletal muscle activity, and a stainless-steel screw
electrode was implanted in the nasal bone. All the electrode leads were soldered to a minia‐
ture connector plug (39F1401, Newark Electronics, Schaumburg, IL, USA), and the assembly
was fixed to the screw electrodes and skull using acrylic dental cement (Biocryl-RN, Galenika
a.d. Beograd, Serbia).
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Figure 1. Schematic illustration of the experimental procedure in the animal studies of the impaired PPT choliner‐
gic control. Operative procedure for the stereotaxic implantation of the chronic EEG and EMG electrodes for sleep re‐
cording and the stereotaxically guided microinfusion for the PPT excitotoxic lesion (Aa-g) with the illustrations of
stereotaxic positions on the rat scull for the EEG electrodes implantation and the PPT lesions (Ab); Sleep recording,
sleep states differentiation and analysis (Ba-c): the analog signals (10 s) recorded from the sensorimotor (SMCx) and
motor (MCx) cortex, and EMG from dorsal nuchal muscle (Ba); an individual example of the final scattergram for
Wake/NREM/REM differentiation during the 6 h of sleep recording. Each symbol corresponds to one 10 s epoch. W
cluster – Wake 10 s epochs, dots; NR cluster – NREM 10 s epochs, circles; R cluster – REM 10 s epochs, crosses (Bb);
and an example of the group probability density distributions of the sleep/wake state-related EEG frequency band rel‐
ative amplitudes/6 h in bilateral PPT lesion vs. control, representing the EEG microstructure during NREM, with statis‐
tically significant attenuation (the left shifted green delta amplitude group distribution) and augmentation (the right
shifted green beta amplitude group distribution) of the corresponding EEG relative amplitudes (Bc). Typical examples
of the control PPT (Ca) and the bilateral PPT lesion (Cb), histologically identified by NADPH-diaphorase staining and
quantified throughout the overall PPT rostro-caudal dimension (6.90 – 8.60 mm caudal from bregma), with the choli‐
nergic neuronal loss expressed as the group mean percent difference of the NADPH-diaphorase positive cells with re‐
spect to control, taken as 100% for each stereotaxic range, and also per each brain side (Cc). PPTg – pedunculopontine
tegmental nucleus; xscp – decussation of the superior cerebellar peduncle; MnR – median raphe nucleus. Scale bar is
200 μm.
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2.3. Excitotoxic lesion of the PPT
During surgical procedure for the EEG and EMG electrodes implantations we performed the
bilateral PPT lesions (Figure 1A). These excitotoxic lesions were induced by the stereotaxical‐
ly guided microinfusion of 0.1 M ibotenic acid (IBO)/ 0.1 M phosphate buffered saline (PBS)
bilaterally into the PPT (A/P: –7.8 mm from bregma; R/L: 1.9 mm from sagittal suture; D/V: 7.0
mm from the brain surface), using a Digital Lab Standard Stereotaxic Instrument with a
Hamilton syringe (1 μl). The IBO (Sigma; pH = 7.4) concentration was chosen on the basis of
previous studies [49–53, 55]. The microinfusions were introduced at a volume of 100 nl, using
a single, 60 s pulse.
2.4. Sleep recording
At the end of surgical procedure, the scalp wounds were sutured and the rats were allowed
to recover 13 days before their adaptation to the recording cable and plexiglass chamber (30
cm x 30 cm x 30 cm) for one day. The EEG and EMG activities were carried from the connec‐
tor plug on the rat head by cable, passed through a sealed port on the recording box, and
differentially recorded. Differential mode consisted of 6 inputs (left MCx, right MCx, left
SMCx, right SMCx, left EMG, right EMG), each with a (+) on the left and a (–) on the right side
and all with the same ground (a screw electrode implanted in the nasal bone). The activities
were displayed on a computer monitor, and stored on disk for further off-line analysis (Figure
1Ba). After conventional amplification and filtering (0.3–100 Hz band pass; A-M System Inc.
Model 3600, Carlborg, WA, USA), the analog data were digitized (sampling frequency 256/s),
and recorded for 6 h, during the normal inactive circadian phase for rats (from 9 a.m. to 3 p.m.),
using DataWave SciWorks Experimenter Version 8.0 (Datawave Technologies, Longmont, CO,
USA).
Additionally, we have followed the impact of different anesthetized states of surgical level in
all the experimental groups, during 20 min of ketamine/diazepam or pentobarbital anesthe‐
sia [52], and we recorded EEG and respiratory movements using the piezo electric strain
gauge (Infant-Ped Sleepmate Technologies, Midlothain, VA).
The stability of the anesthesia was estimated on the bases of the observed loss of conscious‐
ness, muscle atonia, absence of tail-pinch, ear-pinch (analgesia) and corneal reflexes before the
onset of each 20 min recording of the stable anesthetized state, and on the bases of polygraph‐
ic recording during the experimental procedure, including regular breathing pattern [52]. In
all acute experiments, the anesthesia was administered at 9 a.m.
2.5. Identification and quantification of the PPT lesion
We identified the PPT lesions by NADPH - diaphorase histochemistry [56], and we quantified
the PPT cholinergic cell loss using Image J 1.46 software. NADPH - diaphorase positive cells
were counted in three 40 μm thick coronal sections per each brain within an overall rostro-
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caudal PPT dimension [49–53]. The number of NADPH - diaphorase positively stained cells
was intended to provide an estimate of the lesion damage or the cholinergic neuronal numbers,
rather than an attempt to determine the absolute numbers of cholinergic neurons within the
PPT. The cholinergic neuronal loss was expressed per each brain side, and per each defined
stereotaxic range, within the overall PPT rostro-caudal dimension, as the percent difference of
NADPH - diaphorase positive cells versus the controls. Namely, all percent differences were
expressed with respect to the mean control absolute numbers per each stereotaxic range taken
as 100%. All statistical analyses for the PPT cholinergic cells number changes were done using
nonparametric Mann-Whitney U two-tailed tests [49–53]. We have shown that by using a 100
nl microinfusion of 0.1 M IBO for the excitotoxic PPT lesion we induced the partial bilateral
lesions of the PPT pars compacta (as dominantly cholinergic part of the PPT), and we achieved
the selectivity of the lesions within the PPT limits (Figure 1Ca,b). We have demonstrated
(Figure 1Ca,b,c) that the cholinergic neuronal loss induced by our methodological approach
was > 20% throughout the overall rosto-caudal dimension within the each brain side [49–53].
2.6. Data analysis
Analysis of the recorded signals was conducted using original software we developed [48–53]
using MATLAB 6.5 (Figure 1Bb,c). We applied Fourier analysis to the signals acquired
throughout each 6 h recording (2160 10 s Fourier epochs), and each 10 s epoch was differenti‐
ated as Wake, NREM or REM state (Figure 1Bb) for further analysis of the Wake, NREM and
REM related EEG relative amplitudes of all the conventional frequency bands (δ = 0.3–4 Hz; θ
= 4.1–8 Hz; σ = 10.1–15 Hz; β = 15.1–30 Hz; γ = 30.1–50 Hz).
We particularly analyzed two distinct REM clusters that emerged within the scattergrams, and
each REM 10 s epoch was differentiated, based on the EMG power, as REM with higher muscles
tone (REM1) or REM with atonia (REM2). Differentiation of the Wake epochs from sleep
epochs, and further differentiation of the NREM and REM/REM1/REM2 epochs was ach‐
ieved using the two clusters K means algorithm (Figure 1Bb; Figure 2A). We improved these
differentiation results by using the logarithmic values of quantities on both axes [48–53].
To analyze the sleep/wake state related EEG amplitude changes we calculated group proba‐
bility density distributions of all the Wake, NREM and REM/REM1/REM2 conventional EEG
frequency bands relative amplitudes over 6 h, using the Probability Density Estimate (PDE)
routine supplied with MATLAB 6.5 (Figure 1Bc; Figure 2B). In order to eliminate any influence
from absolute signal amplitude variations on the recordings, we computed the relative Fourier
amplitudes [48–53, 57]:
(RA)b =
∑
b
Amp
∑
tot
Amp , b ={δ, θ, σ, β, γ}. (1)
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Figure 2. Topography of the REM sleep alterations following the PPT lesion. Examples of the final scattergrams for
the Wake/NREM/REM/REM1/REM2 differentiation within the sensorimotor (SMCx) and motor (MCx) cortex during 6
h of sleep recordings (A) of the control (Control) and bilaterally PPT lesioned rat (PPT lesion). In all scattergrams the
Wake 10 s epochs (W cluster, crosses) are transferred to these final scattergrams from the preceding Wake/Sleep differ‐
entiations. NR cluster, circles – NREM 10 s epoch; R1, R2, clusters, dots – REM1, REM2 10 s epochs (A); REM/REM1/
REM2 EEG microstructure within the SMCx and MCx cortex of the control (Control, blue line) and bilaterally PPT
lesioned rat (PPT lesion, green line); p values correspond to the statistically significant Mann-Whitney U two-tailed
comparisons (B); REM/REM1/REM2 group coherence spectra between the SMCx or MCx EEGs and the dorsal nuchal
muscle EMGs of the control (Control, blue line) and bilaterally PPT lesioned rat (PPT lesion, green line) with the inserts
of their corresponding group mean relative amplitude EEG and EMG spectra used for the corticomuscular coherence
analysis (C).
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For each sleep/wake state and each frequency band, PDE analysis was performed on the
ensembles of relative amplitudes by pooling measured values (RA)b from all animals belong‐
ing to a specific experimental group (Figure 1Bc; Figure 2B; Figure 3A; Figure 4Ac; Figure 4Bc).
Figure 3. Differing impact of aging on the EEG microstructure during REM sleep in the PPT lesioned rats vs. con‐
trol rats at the onset (3 months), and at two last (4.5 months and 5.5 months) aging follow-up periods. The group
probability density distributions of the EEG sigma relative amplitude/6 h during REM sleep depict the age related
augmentation of the REM sigma amplitude within the motor cortex (MCx) in the PPT lesioned rats vs. control rats (the
right shifted green distributions) - p values correspond to the obtained significant results of Mann-Whitney U two-
tailed tests (A). Individual examples of the MCx REM spectrograms across the overall aging follow up period during
the bilateral PPT lesions vs. controls (B), with their typical 10 s analog EEG and EMG signals during REM (C) used for
the construction of REM spectrograms as well as for the corticomuscular coherence analysis during REM. For all REM
spectrograms the EEG 10 s epochs during REM were extracted and concatenated in the same order as they occurred in
a real-time domain during the whole 6 h sleep of each rat, and at each time during aging follow up period. The group
mean coherence spectra between the MCx EEG and the dorsal nuchal muscle EMG during REM in the bilateral PPT
lesions vs. controls (D). Aging consistently increased the MCx delta, theta, sigma and beta drives during the bilateral
PPT lesion (green arrows).
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Additionally, we have analyzed the Wake, NREM and REM/REM1/REM2 corticomuscular
coherences (CMCs) separately for each experimental group, each state, and for all the
conventional EEG frequency bands (Figure 2C; Figure 3D), using the SMCx or MCx EEG, and
the EMG of the dorsal nuchal muscles [51, 53, 57]. CMC values were calculated using the
“cohere” routine of the MATLAB 6.5 Signal Processing Toolbox. It actually computes the
magnitude squared coherence between signals x(EEG) and y(EMG) as:
Figure 4. Impact of ketamin/diazepam (A) and pentobarbital (B) anesthetic regimens at surgical level on EEG mi‐
crostructure and respiratory pattern in the bilaterally PPT lesioned rat vs. control rat. Individual examples of the
analog 10 s EEG and respiratory signals (a), as well as their EEG spectrograms (b) and the group EEG microstructure
during 20 min of stable anesthetized state (c) in the bilaterally PPT lesioned vs. control rats. The p values correspond to
the statistically significant Mann-Whitney U two-tailed comparisons.
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2( )( ) ( ) ( )
xy
xy
xx yy
P fC f P f P f= (2)
where Pxy(f) stands for the cross spectrum of x and y, while Pxx(f) and Pyy(f) denote the power
spectra of the two signals. All Pxy, Pxx, and Pyy values were determined for every 10 s of each 6
h recording, and for each frequency within the overall 0.3 - 50 Hz range, with 0.1 Hz resolution.
Namely, previously identified Wake/NREM/REM/REM1/REM2 EEG and EMG 10 s epochs
were concatenated and pooled within each experimental group of rats. Then, the CMC spectra
were calculated for every 60 min of Wake and NREM, and for every 30 min of REM/REM1/
REM2, using 10 s FFT epochs for the MATLAB “cohere” routine, resulting in 0.1 Hz frequen‐
cy resolution. Then, the CMC values within each conventional frequency band (δ, θ, σ, β, γ)
were averaged for each spectrum, and finally their means were calculated from the collec‐
tion of all available CMC spectra, for each state.
We have also drawn the REM sleep EEG spectrograms (Figure 3B) or the EEG spectrograms
of distinct anesthetized states at surgical level (Figure 4Ab, Figure 4Bb) using the same Fourier
analysis parameters: a 10 s Fourier epoch, resulting in 0.1 Hz y-axis frequency resolution; a 10
s moving Fourier epoch step, yielding the same x-axis time resolution.
For the respiratory pattern time-domain analysis during anesthesia, the respiratory signal was
passed through a 0.5–5 Hz band pass filter to remove baseline drift and attenuate the high
frequency noise and we used our originally developed analysis for breath detection, differen‐
tiation, and the quantification of the eupnea, bradypnea/apnea and sigh breath-to-breath
intervals within the respiratory pattern. All the details for the respiratory pattern analysis are
explained elsewhere [52].
For the statistical analysis of PDE/6 h and CMC/6 h we calculated the relative amplitude means
for Wake and NREM per each 60 min, and for REM/REM1/REM2 per each 30 min. Further, we
employed the Kruskal-Wallis ANOVA and Mann-Whitney U two-tailed tests for the statisti‐
cal analysis of all group means over 6 h: the group mean durations of Wake, NREM, and REM/
REM1/REM2; the group mean number and group mean duration of Wake, NREM and REM/
REM1/REM2 episodes; the group means of Wake, NREM and REM/REM1/REM2 EEG relative
amplitudes for all frequency bands; and the group CMC means of Wake, NREM and REM/
REM1/REM2. In all cases the differences were considered statistically significant for p ≤ 0.05.
3. Disorders of sleep and motor control in the rat model of Parkinson’s
disease cholinergic neuropathology
Our studies in the rat model “in vivo” demonstrated that the severe PPT cholinergic neuro‐
nal loss (the severe thalamo-cortical cholinergic control impairment) did not change the sleep/
wake states architecture, but disturbed the sleep/wake state transitions structure and aug‐
mented cortical activation during all sleep/wake states [49]. Beside the “tonically” increased
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Wake/REM and REM/Wake transitions, the bilateral PPT lesion was expressed from the
onset (14 days following lesion) as a generalized Wake, NREM and REM beta amplitude
augmentation, which was sustainable for 5 weeks. This effect was followed from the onset by
the NREM delta attenuation and REM gamma augmentation. In addition, there was the Wake
delta attenuation from 21 days after the PPT lesion [49].
Furthermore, our studies have shown for the first time that the bilateral PPT cholinergic
neuronal loss in rat was differently expressed in sensorimotor vs. motor cortex (Figure 2A, B),
and the differing EEG microstructure and transition structure, particularly within the motor
cortex and during NREM and REM sleep are the hallmarks of lesion [50]. Moreover, the
bilateral PPT lesion increased a likelihood of the emergence of two REM sleep states [51],
particularly within the motor cortex (Figure 2A): REM1 (REM without atonia, or “sigma
coherent REM”), and REM2 (REM with atonia, or “theta coherent REM”). Namely, aside from
the differential total EMG power of the dorsal nuchal musculature (Figure 2A), REM1 and
REM2 have the topographically distinct EEG microstructures (Figure 2B) and cortical
locomotor drives (Figure 2C) from the sensorimotor and motor cortices to dorsal nuchal
muscles. These PPT lesion induced alteration of the cortical drives are commonly expressed
as the impaired theta and sigma cortico-muscular coherences [51]. Although the bilateral PPT
lesion altered both cortical drives during both REM states [51], its impact was more severe
during REM2 state (healthy REM, REM with atonia), and more severely through the sensori‐
motor cortical drive (there were the impaired theta, sigma, beta and gamma coritco-muscu‐
lar coherences). These results indicate the simultaneous breakdown of the PPT cholinergic
direct ascending thalamo-coritcal control, and the indirect descending control of the REM sleep
atonia regulatory circuitry, for the emergence of two differential REM states following the
bilateral PPT lesion in rats [51].
We have also demonstrated the age-related and topographically specific EEGs and cortical
drives alterations during sleep in the PPT lesioned rats (Figure 3). The hallmark of earlier aging
onset in the PPT lesioned rats vs. physiological controls was the augmented EEG sigma
amplitude within the motor cortex during REM (Figure 3A, B, C), as the unique pathologi‐
cal phenomenon [53]. Beside this EEG microstructure disorder during REM sleep, we have
evidenced for the first time the altered cortical drives as the hallmarks of the earlier aging onset
during severely impaired PPT cholinergic control (Figure 3D). This compensatory and aging
induced plasticity was differently expressed through the sensorimotor cortical drive altera‐
tions, but it was broadly and commonly expressed through the motor cortical drive altera‐
tions during all the sleep/wake states [53]. Namely, during severely impaired PPT thalamo-
cortical innervation aging consistently increased the motor cortical delta, theta, sigma and beta
drives during NREM and REM sleep (Figure 3D).
Furthermore, we have shown that distinct anesthetic regimens at surgical level were ex‐
pressed differently in the bilaterally PPT lesioned rats (the rat model of cholinergic PD
neuropathology) vs. physiological controls (Figure 4A, B) in terms of the EEG microstruc‐
ture, respiratory pattern, and post-anesthesia sleep [52]. Namely, the ketamine/diazepam
anesthesia induced more alterations in the EEG microstructure and respiratory pattern (Figure
4A) than did the pentobarbital anesthesia (Figure 4B) in the PPT lesioned rats vs. physiologi‐
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cal controls [52]. Although the ketamine/diazepam anesthesia at surgical level induced the
apneustic breathing pattern in the PPT lesioned rats, the equal time to establish an anesthe‐
tized state in the PPT lesioned rats vs. control rats, and the long-term post-anesthesia sup‐
pressive effect on the augmented cortical activation during NREM (the augmented beta and
theta amplitudes during NREM as a hallmarks of the PPT lesion), suggested the ketamine/
diazepam anesthesia as potentially more beneficial both for anesthesia induction and post-
anesthesia sleep in the surgical procedures of elderly, Parkinson’s and Alzheimer’s patients.
4. Discussion
Our studies have shown that the sleep/wake states related disturbances were topographical‐
ly differently expressed within the sensorimotor and motor cortex in terms of their EEG
microstructure and transitions structure, particularly during NREM and REM sleep, in the rat
model of severely impaired PPT cholinergic thalamo-cortical innervation [49, 50]. Moreover,
we have evidenced the emergence of two REM sleep states in the bilateral PPT lesioned rats,
differential with regard to the total EMG power, the topographically distinct EEG microstruc‐
tures and the sensorimotor and motor cortical drives to the dorsal nuchal muscles. These
altered cortical drives were commonly expressed during both REM states, as the impaired beta
oscillation drive [51]. In addition, the sensorimotor cortical drive was altered more severely
during “healthy” REM (REM with atonia, theta REM) than during the emerged pathological
REM (REM without atonia, sigma REM).
It is well known that the output of the basal ganglia (the efferents from globus palidus internus
and substantia nigra pars reticulata) is sent primarily to thalamus and from there to the frontal
cortex, forming the partially closed cortico-basal ganglia loop. PPT, as the main source of
thalamo-cortical cholinergic innervation, monosynaptically innervates the substantia nigra
and to less extent the globus palidus internus [58], but through its descending cholinergic
efferents indirectly promotes REM sleep atonia [59–61]. Therefore, the degeneration of PPT
cholinergic neurons could underlie the motor symptoms in patients with PD and RBD [59].
Since the PPT may be severely affected by PD pathology, it is regarded as a promising target
for therapeutic deep-brain stimulation [59].
However, our understanding of the PPT role in PD pathogenesis is limited by the lack of a
suitable model of PPT cholinergic neuronal degeneration. All animal models [62–65], the toxic
and transgenic animal models, have their own specificities and limitations that must be
carefully taken into consideration when choosing the model to be used, and when interpret‐
ing the results. For example, recent studies [66, 67] demonstrated different results within the
PPT, as a consequence of the substantia nigra dopaminergic neuronal loss caused by 6-OHDA
or Lactacystin: mostly non-cholinergic PPT neuronal loss [67] vs. mostly PPT cholinergic
loss [66]. We have overviewed our results in the animal model of severe PPT cholinergic
neuropathology (the rat model of PD cholinergic neuropathology) to provide new insights into
the importance and relevance of thalamo-cortical cholinergic system regulatory role in sleep
and motor control in PD.
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